Table 2.

Summary of Optical Changes Reported Across Applications

Activity	Redox ratio	Average NAD(P)H lifetime	Ratio free:bound NAD(P)H
Cancerous transformation (3, 48, 59, 66, 67, 77, 88, 105, 112, 118, 119)	↓	↓	↑
Increased metastatic potential (2, 52, 97)	↑
Response to cancer treatment (85, 86, 106–108, 110)	↑	↓/↑	↓/↑
Parkinson's disease (neurons) (96)	↑		↓
Parkinson's disease (astrocytes) (96)	↑		↑
Thermal stress (19)	↑		↓
De novo fatty acid synthesis (18, 72, 75)	↓
Stem cell differentiation (29, 34, 60, 61, 75, 78, 92, 93, 95)	↓/↑		↓/↑
Hepatitis C infection (58)		↓
Huntington's disease (80)			↑
Calorie restriction (111, 122)	↑
Myocardial infarction (89)	↑
Increased cellular proliferation (43, 73, 74)	↓	↓
Effect of type I diabetes (1, 74)	↓
Antioxidant treatment for diabetes (1)	↑